Patent application number | Description | Published |
20090175801 | CNS-TUMOR TREATMENT METHOD AND COMPOSITION - A method, aerosol composition, and aerosolizing device for treating a brain tumor in a subject are disclosed. The method includes intranasally administering to the subject, an amount of a telomerase inhibitor, such as an oligonucleotide telomerase inhibitor, effective to inhibit growth of the tumor in the subject. | 07-09-2009 |
20090286853 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION - Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics. | 11-19-2009 |
20100016416 | Oligonucleotide Conjugates - Oligonucleotide conjugates, where an oligonucleotide is covalently attached to an aromatic system, are provided. In particular embodiments the oligonucleotide is complementary to the RNA component of human telomerase and is covalently attached to a nucleobase via an optional linker. The conjugates inhibit telomerase enzyme activity. | 01-21-2010 |
20110294213 | 2'-ARABINO-FLUOROOLIGONUCLEOTIDE N3'-P5' PHOSPHORAMIDATES: THEIR SYNTHESIS AND USE - Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2′-arabino-fluoronucleoside and an internucleoside 3′-NH—P(═O)(OR)—O-5′ linkage, where R is a positively charged counter ion or hydrogen, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive phosphoramidate 2′-aribino-fluorooligonucleotides have a high RNA binding affinity to complementary nucleic acids and are base and acid stable. | 12-01-2011 |
20120129918 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION - Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics. | 05-24-2012 |
20120329858 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION - Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics. | 12-27-2012 |
20130065950 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION - Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics. | 03-14-2013 |
20130253034 | 2'-Arabino-Fluorooligonucleotide N3'-->P5' Phosphoramidates: Their Synthesis and Use - Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2′-arabino-fluoronucleoside and an internucleoside | 09-26-2013 |
20130296405 | Compounds Having Anti-Adhesive Effects on Cancer Cells - Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3′->P5′ thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells. | 11-07-2013 |
20140349292 | OLIGONUCLEOTIDE N3'-->P5' THIOPHOSPHORAMIDATES: THEIR SYNTHESIS AND USE - Oligonucleotides with a novel sugar-phosphate backbone containing at least one internucleoside 3′-NHP(O)(S | 11-27-2014 |